Mutant KRAS is a druggable target for pancreatic cancer.

doi:10.1073/pnas.1314307110

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutant KRAS is a druggable target for pancreatic cancer.

Proceedings of the National Academy of Sciences of the United States of America - 17 Dec 2013

Zorde Khvalevsky Elina, Gabai Racheli, Rachmut Itzhak Haim, Horwitz Elad, Brunschwig Zivia, Orbach Ariel, Shemi Adva, Golan Talia, Domb Abraham J, Yavin Eylon, Giladi Hilla, Rivkin Ludmila, Simerzin Alina, Eliakim Rami, Khalaileh Abed, Hubert Ayala, Lahav Maor, Kopelman Yael, Goldin Eran, Dancour Alan, Hants Yael, Arbel-Alon Sagit, Abramovitch Rinat, Shemi Amotz, Galun Eithan

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet this challenge, we have developed a local prolonged siRNA delivery system (Local Drug EluteR, LODER) shedding siRNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Drug Evaluation, Preclinical

Share to Gene Silencing

Share to Mice, SCID

Share to Pancreatic Neoplasms

Share to ras Proteins

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 24297898
DOI: 10.1073/pnas.1314307110
PMCID: PMC3870687

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant KRAS is a druggable target for pancreatic cancer.PMID 24297898Read ↗

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.Semantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.Semantic proximity Read ↗

Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer.Semantic proximity Read ↗

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.